Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma |
Ozpolat, H. Tahsin
(Bloodworks Research Institute)
Yilmaz, Ebru (Department of Nuclear Medicine, Istanbul School of Medicine) Goksoy, Hasan Sami (Department of Hematology, Istanbul School of Medicine) Ozpolat, Sahre (Department of Biostatistics and Epidemiology, Marmara School of Medicine) Dogan, Oner (Department of Pathology, Istanbul School of Medicine) Unal, Seher Nilgun (Department of Nuclear Medicine, Istanbul School of Medicine) Nalcaci, Meliha (Department of Hematology, Istanbul School of Medicine) |
1 | Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81. DOI |
2 | Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-67. |
3 | El Karak F, Bou-Orm IR, Ghosn M, et al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One 2017;12:e0170299. DOI |
4 | Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. DOI |
5 | Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14. DOI |
6 | Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62. DOI |
7 | National Cancer Institute. Survival. Bethesda, MD: National Cancer Institute, 2018. (Accessed October 2, 2018, at https://progressreport.cancer.gov/after/survival). |
8 | Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009;36(4 Suppl 2):S2-16. DOI |
9 | Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol 2009;11:269-74. DOI |
10 | Fuertes S, Setoain X, Lopez-Guillermo A, et al. The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma. Med Clin (Barc) 2007;129:688-93. DOI |
11 | Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-9. DOI |
12 | McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: bone marrow and blood manifestations. Cancer 1975;36:428-40. DOI |
13 | Mckenna RW. The bone marrow manifestations of Hodgkin's disease, the non-Hodgkin's lymphomas and lymphoma-like disorders. In: Dunphy CH. Neoplastic hematopathology. 1st ed. Baltimore, MD: Williams & Wilkins, 1992:1156. |
14 | Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62-4. DOI |
15 | Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major beta-thalassemia. Clin Nucl Med 2005;30:754-5. DOI |
16 | Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958-63. |
17 | Murata Y, Kubota K, Yukihiro M, Ito K, Watanabe H, Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol 2006;33:999-1004. DOI |
18 | El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatmentnaive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508-14. DOI |
19 | Adams HJ, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RA, de Klerk JM. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol 2015;95:83-9. DOI |
20 | Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-99. DOI |
21 | Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6. DOI |
22 | Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S113-20. DOI |
23 | Heacock L, Weissbrot J, Raad R, et al. PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 2015;204:842-8. DOI |
![]() |